HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a Buy rating on Arrowhead Pharma (NASDAQ: ARWR) and maintained a price target of $120 for the stock. No additional financial figures or strategic changes were mentioned in the article.